Journal: Cancer gene therapy

Article Title: Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers.

doi: 10.1038/sj.cgt.7700900

Figure Lengend Snippet: Figure 1 MHC class I expression and induction by IFN-g in mouse prostate cancer cell lines. TRAMP-C2 and Pr14-2 cell lines were grown in the presence or absence of IFN-g (100 m/ml of growth medium) for 72 h and analyzed for MHC class I molecules, H-2Kb

Article Snippet: 5 106 TRAMP-C2 cells were implanted subcutaneously into the left flank of 6-week-old male C57Bl/6 mice (Harlan, Indianapolis, IN) and when the tumors grew to approximately 80–100 mm3 in volume, they were treated intraneoplastically with 1 107 plaque forming units (PFU) of either G207, G47D, NV1023, NV1034, NV1042 or virus buffer (Mock) on days 0 and 3.

Techniques: Expressing

Journal: Cancer gene therapy

Article Title: Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers.

doi: 10.1038/sj.cgt.7700900

Figure Lengend Snippet: Figure 2 In vitro and in vivo susceptibility of TRAMP-C2 cells to oncolytic HSvs. (a) TRAMP-C2 cells at 20% confluency were infected with G207, G47D or NV1023 or virus buffer (control) at various MOIs and cell viability assessed on days 1, 2, and 3 postinfection. Data shown are percent of uninfected control. These cells were generally resistant to all the viruses except at an MOI of 1.0. (b) Subcutaneous TRAMP-C2 tumors established in male C57Bl/56 mice were treated intraneoplastically on days 0 and 3 with 1 107 PFU of G207, G47D or NV1023 or virus buffer (Mock); n ¼ 7/group. NV1023 was most effective in inhibiting the growth of the tumors as compared to Mock, G207 and G47D (Po0.05, Student’s t-test; days 19, 23) and extending survival of the treated mice (Po0.05 vs Mock, G207 and G47D; Log-rank (Mantel–Cox) test).

Article Snippet: 5 106 TRAMP-C2 cells were implanted subcutaneously into the left flank of 6-week-old male C57Bl/6 mice (Harlan, Indianapolis, IN) and when the tumors grew to approximately 80–100 mm3 in volume, they were treated intraneoplastically with 1 107 plaque forming units (PFU) of either G207, G47D, NV1023, NV1034, NV1042 or virus buffer (Mock) on days 0 and 3.

Techniques: In Vitro, In Vivo, Infection, Virus, Control

Journal: Cancer gene therapy

Article Title: Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers.

doi: 10.1038/sj.cgt.7700900

Figure Lengend Snippet: Figure 3 Efficacy of oncolytic cytokine HSVs in syngeneic mouse prostate cancer models. TRAMP-C2 (a) and Pr14-2 (b) tumors were established subcutaneously in male C57Bl/6 and heterozygous C3(1)/T-Ag mice, respectively, and treated intraneoplastically on days 0 and 3 with 1 107 PFU of NV1023, NV1034 (GM-CSF), NV1042 (IL-12) or virus buffer (Mock); n ¼ 7/group. In both tumor models, NV1042 virus was significantly more effective in tumor growth inhibition (Po0.05, Student’s t-test; from day 7 (TRAMP-C2) and day 17 (Pr14-2) vs Mock, NV1023 and NV1034) as well as prolonging median survival. (TRAMP-C2: 38 days vs 31 days with other treatments; Pr14-2: 75 days vs 54 days with other treatments) (Po0.05, Log-rank (Mantel–Cox) test).

Article Snippet: 5 106 TRAMP-C2 cells were implanted subcutaneously into the left flank of 6-week-old male C57Bl/6 mice (Harlan, Indianapolis, IN) and when the tumors grew to approximately 80–100 mm3 in volume, they were treated intraneoplastically with 1 107 plaque forming units (PFU) of either G207, G47D, NV1023, NV1034, NV1042 or virus buffer (Mock) on days 0 and 3.

Techniques: Virus, Inhibition

Journal: Cancer gene therapy

Article Title: Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers.

doi: 10.1038/sj.cgt.7700900

Figure Lengend Snippet: Figure 4 Efficacy of NV1042 in bilateral mouse prostate cancer models. Subcutaneous TRAMP-C2 (a) and Pr14-2 (b) tumors were established on both flanks of male C57Bl/6 and heterozygous C3(1)/T-Ag mice, respectively, and treated intraneoplastically on days 0, 3, 7, and 10 with 1 107 PFU of NV1023, NV1042 (IL-12) or virus buffer (Mock); n ¼ 11 (TRAMP-C2) or 8 (Pr14-2)/group. In both tumor models, NV1042 significantly inhibited the growth of the inoculated (from day 7 in TRAMP-C2 and day 10 in Pr14-2) and non-inoculated tumor (from day 27 in TRAMP-C2 and day 21 in Pr14-2) (po0.05 vs Mock, NV1023; Student’s t-test).

Article Snippet: 5 106 TRAMP-C2 cells were implanted subcutaneously into the left flank of 6-week-old male C57Bl/6 mice (Harlan, Indianapolis, IN) and when the tumors grew to approximately 80–100 mm3 in volume, they were treated intraneoplastically with 1 107 plaque forming units (PFU) of either G207, G47D, NV1023, NV1034, NV1042 or virus buffer (Mock) on days 0 and 3.

Techniques: Virus

Journal: Cancer gene therapy

Article Title: Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers.

doi: 10.1038/sj.cgt.7700900

Figure Lengend Snippet: Figure 5 Serum and tumor IL-12 levels in virus treated TRAMP-C2 tumors. Subcutaneous TRAMP-C2 tumors were treated intraneo- plastically on days 0 and 3 with 1 107 PFU of NV1023 or NV1042 (IL-12), or virus buffer (Mock); n ¼ 18/virus treatment group; n ¼ 6/ Mock. Groups of three mice were killed on days 4, 6 and 10 (Mock only on day 4) and IL-12 levels measured by ELISA from serum (a) and tumor (b). Data shown is the mean of three mice from each group and the error bars represent s.d. values. Serum IL-12 levels in the virus treated groups on any day post-treatment were not significantly different (NV1042 or NV1023 vs Mock; Student’s t-test). Measurable levels of IL-12 were detected only in NV1042 treated tumors.

Article Snippet: 5 106 TRAMP-C2 cells were implanted subcutaneously into the left flank of 6-week-old male C57Bl/6 mice (Harlan, Indianapolis, IN) and when the tumors grew to approximately 80–100 mm3 in volume, they were treated intraneoplastically with 1 107 plaque forming units (PFU) of either G207, G47D, NV1023, NV1034, NV1042 or virus buffer (Mock) on days 0 and 3.

Techniques: Virus, Enzyme-linked Immunosorbent Assay

Journal: Cancer gene therapy

Article Title: Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers.

doi: 10.1038/sj.cgt.7700900

Figure Lengend Snippet: Figure 6 X-gal staining of TRAMP-C2 tumors inoculated with NV1042. Subcutaneous TRAMP-C2 tumors were treated intraneoplastically on days 0 and 3 with 1 107PFU of NV1042 and harvested on day 4 (a), day 6 (b) and day 10 (c). Tumors sections (10mm) were stained for Lac Z expression by X-gal histochemistry. Maximal staining was observed on day 6 post-treatment, adjoining areas of significant cell death. Magnification: day 4 200; day 6 125 ; day 10 125.

Article Snippet: 5 106 TRAMP-C2 cells were implanted subcutaneously into the left flank of 6-week-old male C57Bl/6 mice (Harlan, Indianapolis, IN) and when the tumors grew to approximately 80–100 mm3 in volume, they were treated intraneoplastically with 1 107 plaque forming units (PFU) of either G207, G47D, NV1023, NV1034, NV1042 or virus buffer (Mock) on days 0 and 3.

Techniques: Staining, Expressing

Journal: Cancer gene therapy

Article Title: Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers.

doi: 10.1038/sj.cgt.7700900

Figure Lengend Snippet: Figure 7 CD31 immunostaining of virus treated TRAMP-C2 tumors. Subcutaneous TRAMP-C2 tumors were treated intraneoplastically on days 0 and 3 with 1 107 PFU of NV1023 or NV1042, or virus buffer (Mock). Tumor sections (10 mm) obtained from mice killed on day 10 were immunostained for CD31 molecules. Photomicrographs ( 400) illustrate that while NV1023 treatment (b) led to a decrease in CD31 staining as compared to the Mock treated group (a), a dramatic reduction in CD31-positive cells was observed in tumors treated with NV1042 (c).

Article Snippet: 5 106 TRAMP-C2 cells were implanted subcutaneously into the left flank of 6-week-old male C57Bl/6 mice (Harlan, Indianapolis, IN) and when the tumors grew to approximately 80–100 mm3 in volume, they were treated intraneoplastically with 1 107 plaque forming units (PFU) of either G207, G47D, NV1023, NV1034, NV1042 or virus buffer (Mock) on days 0 and 3.

Techniques: Immunostaining, Virus, Staining